A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS

Summary

This study is a Single-arm, Open, Prospective, Single-center, Phase Ⅱ Clinical Study ,Target population is Advanced Inoperable Resection of Undifferentiated Pleomorphic Sarcoma (UPS) and Alveolar Soft Tissue Sarcoma (ASPS) . The purpose of this study was to evaluate the safety and efficacy of combination of Camrelizumab and Apatinib in the treatment of unresectable UPS and ASPS

Timeline

Start

2020-07-01

Primary completion

2021-12-31

Completion

2021-12-31

Publications

• Tan H, Wang H, Zhou J, Jiang L, Shi S, Wang W, Chi Y. Camrelizumab Plus Apatinib in Advanced Unresectable Alveolar Soft Part Sarcoma and Undifferentiated Pleomorphic Sarcoma Patients: A Single-Center, Exploratory Case Series. Ther Clin Risk Manag. 2026 Apr 23;22:586907. doi: 10.2147/TCRM.S586907. eCollection 2026.

Drugs

Indications